Abstract
Understanding rare genetic brain disorders with overlapping neurological and psychiatric phenotypes is of increasing importance given the potential for developing disease models that could help to understand more common, polygenic disorders. However, the traditional clinical boundaries between neurology and psychiatry result in frequent segregation of these disorders into distinct silos, limiting cross-specialty understanding that could facilitate clinical and biological advances. In this Review, we highlight multiple genetic brain disorders in which neurological and psychiatric phenotypes are observed, but for which in-depth, cross-spectrum clinical phenotyping is rarely undertaken. We describe the combined phenotypes observed in association with genetic variants linked to epilepsy, dystonia, autism spectrum disorder and schizophrenia. We also consider common underlying mechanisms that centre on synaptic plasticity, including changes to synaptic and neuronal structure, calcium handling and the balance of excitatory and inhibitory neuronal activity. Further investigation is needed to better define and replicate these phenotypes in larger cohorts, which would help to gain greater understanding of the pathophysiological mechanisms and identify common therapeutic targets.
Key points
-
Rare genetic brain disorders frequently involve both neurological and psychiatric phenotypes, but detailed, cross-spectrum clinical phenotyping is rarely undertaken.
-
Improved clinical phenotypic understanding of these single gene disorders is important, given the potential for developing genetic model systems to aid understanding of the underlying pathophysiological mechanisms.
-
Potential shared pathophysiological mechanisms include disruption to synaptic plasticity, synaptic and neuronal structure, the balance of excitatory and inhibitory neuronal activity and calcium handling.
-
Further mechanistic understanding of the overlap between neurological and psychiatric phenotypes will increase opportunities for discovery of novel therapeutic targets in multiple brain disorders.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mencacci, N. E. et al. Dystonia genes functionally converge in specific neurons and share neurobiology with psychiatric disorders. Brain 143, 2771–2787 (2020).
Cunningham, A. C. et al. Movement disorder phenotypes in children with 22q11.2 deletion syndrome. Mov. Disord. 35, 1272–1274 (2020).
Liu, Y. et al. A selective review of the excitatory-inhibitory imbalance in schizophrenia: underlying biology, genetics, microcircuits, and symptoms. Front. Cell Dev. Biol. 9, 664535 (2021).
Thygesen, J. H. et al. Neurodevelopmental risk copy number variants in adults with intellectual disabilities and comorbid psychiatric disorders. Br. J. Psychiatry 212, 287–294 (2018).
Mollon, J., Almasy, L., Jacquemont, S. & Glahn, D. C. The contribution of copy number variants to psychiatric symptoms and cognitive ability. Mol. Psychiatry https://doi.org/10.1038/s41380-023-01978-4 (2023).
Moreno-De-Luca, A. et al. Developmental brain dysfunction: revival and expansion of old concepts based on new genetic evidence. Lancet Neurol. 12, 406–414 (2013).
Brainstorm Consortium et al. Analysis of shared heritability in common disorders of the brain. Science 360, https://doi.org/10.1126/science.aap8757 (2018).
Matsuo, M., Maeda, T., Sasaki, K., Ishii, K. & Hamasaki, Y. Frequent association of autism spectrum disorder in patients with childhood onset epilepsy. Brain Dev. 32, 759–763 (2010).
Fiest, K. M. et al. Depression in epilepsy: a systematic review and meta-analysis. Neurology 80, 590–599 (2013).
Scott, A. J., Sharpe, L., Hunt, C. & Gandy, M. Anxiety and depressive disorders in people with epilepsy: a meta-analysis. Epilepsia 58, 973–982 (2017).
Aaberg, K. M. et al. Comorbidity and childhood epilepsy: a nationwide registry study. Pediatrics 138, e20160921 (2016).
Josephson, C. B. et al. Association of depression and treated depression with epilepsy and seizure outcomes: a multicohort analysis. JAMA Neurol. 74, 533–539 (2017).
Hesdorffer, D. C. et al. Occurrence and recurrence of attempted suicide among people with epilepsy. JAMA Psychiatry 73, 80–86 (2016).
Berkvens, J. J. et al. Autism and behavior in adult patients with Dravet syndrome (DS). Epilepsy Behav. 47, 11–16 (2015).
Scheffer, I. E. & Nabbout, R. SCN1A-related phenotypes: epilepsy and beyond. Epilepsia 60, S17–S24 (2019).
Claes, L. et al. De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy. Hum. Mutat. 21, 615–621 (2003).
Skluzacek, J. V., Watts, K. P., Parsy, O., Wical, B. & Camfield, P. Dravet syndrome and parent associations: the IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief. Epilepsia 52, 95–101 (2011).
Ragona, F. Cognitive development in children with Dravet syndrome. Epilepsia 52, 39–43 (2011).
Wolff, M., Casse-Perrot, C. & Dravet, C. Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings. Epilepsia 47, 45–48 (2006).
Li, B. M. et al. Autism in Dravet syndrome: prevalence, features, and relationship to the clinical characteristics of epilepsy and mental retardation. Epilepsy Behav. 21, 291–295 (2011).
Villeneuve, N. et al. Cognitive and adaptive evaluation of 21 consecutive patients with Dravet syndrome. Epilepsy Behav. 31, 143–148 (2014).
Ouss, L. et al. Autism spectrum disorder and cognitive profile in children with Dravet syndrome: delineation of a specific phenotype. Epilepsia Open. 4, 40–53 (2019).
Weiss, L. A. et al. Sodium channels SCN1A, SCN2A and SCN3A in familial autism. Mol. Psychiatry 8, 186–194 (2003).
Djemie, T. et al. Pitfalls in genetic testing: the story of missed SCN1A mutations. Mol. Genet. Genom. Med. 4, 457–464 (2016).
Dibbens, L. M. et al. X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. Nat. Genet. 40, 776–781 (2008).
van Harssel, J. J. et al. Clinical and genetic aspects of PCDH19-related epilepsy syndromes and the possible role of PCDH19 mutations in males with autism spectrum disorders. Neurogenetics 14, 23–34 (2013).
Kolc, K. L. et al. A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy. Transl. Psychiatry 10, 127 (2020).
Trivisano, M. et al. Defining the electroclinical phenotype and outcome of PCDH19-related epilepsy: a multicenter study. Epilepsia 59, 2260–2271 (2018).
Vlaskamp, D. R. M. et al. Schizophrenia is a later-onset feature of PCDH19 girls clustering epilepsy. Epilepsia 60, 429–440 (2019).
Weckhuysen, S. et al. KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann. Neurol. 71, 15–25 (2012).
Malerba, F. et al. Genotype-phenotype correlations in patients with de novo KCNQ2 pathogenic variants. Neurol. Genet. 6, e528 (2020).
Jiang, Y. H. et al. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am. J. Hum. Genet. 93, 249–263 (2013).
Milh, M. et al. Similar early characteristics but variable neurological outcome of patients with a de novo mutation of KCNQ2. Orphanet J. Rare Dis. 8, 80 (2013).
Millichap, J. J. et al. KCNQ2 encephalopathy: features, mutational hot spots, and ezogabine treatment of 11 patients. Neurol. Genet. 2, e96 (2016).
Siracusano, M., Marcovecchio, C., Riccioni, A., Dante, C. & Mazzone, L. Autism spectrum disorder and a de novo Kcnq2 gene mutation: a case report. Pediatr. Rep. 14, 200–206 (2022).
Kim, E. C. et al. Heterozygous loss of epilepsy gene KCNQ2 alters social, repetitive and exploratory behaviors. Genes. Brain Behav. 19, e12599 (2020).
Miceli, F. et al. KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanism. EBioMedicine 81, 104130 (2022).
Carvill, G. L. et al. GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat. Genet. 45, 1073–1076 (2013).
Mangano, G. D. et al. De novo GRIN2A variants associated with epilepsy and autism and literature review. Epilepsy Behav. 129, 108604 (2022).
Lemke, J. R. et al. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat. Genet. 45, 1067–1072 (2013).
Strehlow, V. et al. GRIN2A-related disorders: genotype and functional consequence predict phenotype. Brain 142, 80–92 (2019).
Li, J. et al. De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases. Hum. Mutat. 40, 2393–2413 (2019).
Singh, T. et al. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature 604, 509–516 (2022).
Allen, N. C. et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 40, 827–834 (2008).
Amitai, N. & Markou, A. Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol. Psychiatry 68, 5–16 (2010).
Tarabeux, J. et al. Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl. Psychiatry 1, e55 (2011).
O’Roak, B. J. et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat. Genet. 43, 585–589 (2011).
Gai, X. et al. Rare structural variation of synapse and neurotransmission genes in autism. Mol. Psychiatry 17, 402–411 (2012).
Maksemous, N., Roy, B., Smith, R. A. & Griffiths, L. R. Next-generation sequencing identifies novel CACNA1A gene mutations in episodic ataxia type 2. Mol. Genet. Genom. Med. 4, 211–222 (2016).
Terwindt, G. et al. Mutation analysis of the CACNA1A calcium channel subunit gene in 27 patients with sporadic hemiplegic migraine. Arch. Neurol. 59, 1016–1018 (2002).
Rajakulendran, S. et al. Genetic and functional characterisation of the P/Q calcium channel in episodic ataxia with epilepsy. J. Physiol. 588, 1905–1913 (2010).
Indelicato, E. & Boesch, S. From genotype to phenotype: expanding the clinical spectrum of CACNA1A variants in the era of next generation sequencing. Front. Neurol. 12, 639994 (2021).
Damaj, L. et al. CACNA1A haploinsufficiency causes cognitive impairment, autism and epileptic encephalopathy with mild cerebellar symptoms. Eur. J. Hum. Genet. 23, 1505–1512 (2015).
van Wamelen, D. J. et al. Cross-sectional analysis of the Parkinson’s disease non-motor international longitudinal study baseline non-motor characteristics, geographical distribution and impact on quality of life. Sci. Rep. 11, 9611 (2021).
Ozelius, L. J. et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat. Genet. 17, 40–48 (1997).
Bailey, G. A., Rawlings, A., Torabi, F., Pickrell, W. O. & Peall, K. J. Longitudinal analysis of the relationship between motor and psychiatric symptoms in idiopathic dystonia. Eur. J. Neurol. 29, 3513–3527 (2022).
Wadon, M. E. et al. Clinical and genotypic analysis in determining dystonia non-motor phenotypic heterogeneity: a UK Biobank study. J. Neurol. 269, 6436–6451 (2022).
Doheny, D. O. et al. Phenotypic features of myoclonus-dystonia in three kindreds. Neurology 59, 1187–1196 (2002).
Hess, C. W. et al. Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology 68, 522–524 (2007).
Peall, K. J., Waite, A. J., Blake, D. J., Owen, M. J. & Morris, H. R. Psychiatric disorders, myoclonus dystonia, and the epsilon-sarcoglycan gene: a systematic review. Mov. Disord. 26, 1939–1942 (2011).
Peall, K. J. et al. SGCE mutations cause psychiatric disorders: clinical and genetic characterization. Brain 136, 294–303 (2013).
Peall, K. J. et al. Psychiatric disorders, myoclonus dystonia and SGCE: an international study. Ann. Clin. Transl. Neurol. 3, 4–11 (2016).
van Tricht, M. J. et al. Cognition and psychopathology in myoclonus-dystonia. J. Neurol. Neurosurg. Psychiatry 83, 814–820 (2012).
Heiman, G. A. et al. Increased risk for recurrent major depression in DYT1 dystonia mutation carriers. Neurology 63, 631–637 (2004).
Heiman, G. A. et al. Obsessive-compulsive disorder is not a clinical manifestation of the DYT1 dystonia gene. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 361–364 (2007).
Liu, D., Cao, H., Kural, K. C., Fang, Q. & Zhang, F. Integrative analysis of shared genetic pathogenesis by autism spectrum disorder and obsessive-compulsive disorder. Biosci. Rep. 39, BSR20191942 (2019).
Hahn, H. et al. Neurologic and psychiatric manifestations in a family with a mutation in exon 2 of the guanosine triphosphate-cyclohydrolase gene. Arch. Neurol. 58, 749–755 (2001).
Van Hove, J. L. et al. Expanded motor and psychiatric phenotype in autosomal dominant Segawa syndrome due to GTP cyclohydrolase deficiency. J. Neurol. Neurosurg. Psychiatry 77, 18–23 (2006).
Tadic, V. et al. Dopa-responsive dystonia revisited: diagnostic delay, residual signs, and nonmotor signs. Arch. Neurol. 69, 1558–1562 (2012).
Fuchs, T. et al. Mutations in GNAL cause primary torsion dystonia. Nat. Genet. 45, 88–92 (2013).
Vuoristo, J. T. et al. Sequence and genomic organization of the human G-protein Golfɑ gene (GNAL) on chromosome 18p11, a susceptibility region for bipolar disorder and schizophrenia. Mol. Psychiatry 5, 495–501 (2000).
Zarrei, M. et al. A large data resource of genomic copy number variation across neurodevelopmental disorders. NPJ Genom. Med. 4, 26 (2019).
Iossifov, I. et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 515, 216–221 (2014).
Tuchman, R. & Rapin, I. Epilepsy in autism. Lancet Neurol. 1, 352–358 (2002).
Damasio, A. R. & Maurer, R. G. A neurological model for childhood autism. Arch. Neurol. 35, 777–786 (1978).
Jeste, S. S. The neurology of autism spectrum disorders. Curr. Opin. Neurol. 24, 132–139 (2011).
Van Waelvelde, H., Oostra, A., Dewitte, G., Van Den Broeck, C. & Jongmans, M. J. Stability of motor problems in young children with or at risk of autism spectrum disorders, ADHD, and or developmental coordination disorder. Dev. Med. Child. Neurol. 52, e174–e178 (2010).
Kanner, L. Autistic disturbances of affective contact. Acta Paedopsychiatr. 35, 100–136 (1968).
Mouridsen, S. E., Rich, B. & Isager, T. A longitudinal study of epilepsy and other central nervous system diseases in individuals with and without a history of infantile autism. Brain Dev. 33, 361–366 (2011).
Clarke, D. F. et al. The prevalence of autistic spectrum disorder in children surveyed in a tertiary care epilepsy clinic. Epilepsia 46, 1970–1977 (2005).
Hara, H. Autism and epilepsy: a retrospective follow-up study. Brain Dev. 29, 486–490 (2007).
Hallmayer, J. et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch. Gen. Psychiatry 68, 1095–1102 (2011).
Cross-Disorder Group of the Psychiatric Genomics, C. et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 45, 984–994 (2013).
Maenner, M. J. et al. Prevalence of autism spectrum disorder among children aged 8 years – Aautism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2016. MMWR Surveill. Summ. 69, 1–12 (2020).
Ranjan, R. et al. Neurological, psychiatric, and multisystemic involvement of fragile X syndrome along with its pathophysiology, methods of screening, and current treatment modalities. Cureus 15, e35505 (2023).
Kaufmann, W. E. et al. Autism spectrum disorder in fragile X syndrome: cooccurring conditions and current treatment. Pediatrics 139, S194–S206 (2017).
Albizua, I. et al. Descriptive analysis of seizures and comorbidities associated with fragile X syndrome. Mol. Genet. Genom. Med. 10, e2001 (2022).
Farzin, F. et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J. Dev. Behav. Pediatr. 27, S137–S144 (2006).
Clifford, S. et al. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J. Autism Dev. Disord. 37, 738–747 (2007).
Hessl, D. et al. Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am. J. Med. Genet. B Neuropsychiatr. Genet. 139B, 115–121 (2005).
Bourgeois, J. A. et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J. Clin. Psychiatry 72, 175–182 (2011).
Hunter, A. G., Ray, M., Wang, H. S. & Thompson, D. R. Phenotypic correlations in patients with ring chromosome 22. Clin. Genet. 12, 239–249 (1977).
Wilson, H. L. et al. Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J. Med. Genet. 40, 575–584 (2003).
Bonaglia, M. C. et al. Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am. J. Hum. Genet. 69, 261–268 (2001).
Durand, C. M. et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat. Genet. 39, 25–27 (2007).
Leblond, C. S. et al. Meta-analysis of SHANK mutations in autism spectrum disorders: a gradient of severity in cognitive impairments. PLoS Genet. 10, e1004580 (2014).
De Rubeis, S. et al. Delineation of the genetic and clinical spectrum of Phelan–McDermid syndrome caused by SHANK3 point mutations. Mol. Autism 9, 31 (2018).
Gauthier, J. et al. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc. Natl Acad. Sci. USA 107, 7863–7868 (2010).
Kohlenberg, T. M. et al. Psychiatric illness and regression in individuals with Phelan–McDermid syndrome. J. Neurodev. Disord. 12, 7 (2020).
Douzgou, S. et al. The clinical presentation caused by truncating CHD8 variants. Clin. Genet. 96, 72–84 (2019).
Kim, C. et al. A Korean boy with a CHD8 mutation who presented with overgrowth, intellectual disability, and autism. Ann. Pediatr. Endocrinol. Metab. https://doi.org/10.6065/apem.2244130.065 (2023).
Dingemans, A. J. M. et al. The phenotypic spectrum and genotype-phenotype correlations in 106 patients with variants in major autism gene CHD8. Transl. Psychiatry 12, 421 (2022).
Doummar, D. et al. Childhood-onset progressive dystonia associated with pathogenic truncating variants in CHD8. Ann. Clin. Transl. Neurol. 8, 1986–1990 (2021).
Splawski, I. et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119, 19–31 (2004).
Green, E. K. et al. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol. Psychiatry 15, 1016–1022 (2010).
Heyes, S. et al. Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders. Prog. Neurobiol. 134, 36–54 (2015).
Chen, J., Sun, Y., Liu, X. & Li, J. Identification of a novel mutation in the CACNA1C gene in a Chinese family with autosomal dominant cerebellar ataxia. BMC Neurol. 19, 157 (2019).
Rodan, L. H. et al. Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations. Genet. Med. 23, 1922–1932 (2021).
Levy, R. J. et al. A cross-sectional study of the neuropsychiatric phenotype of CACNA1C-related disorder. Pediatr. Neurol. 138, 101–106 (2023).
Cheadle, J. P. et al. Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. Hum. Mol. Genet. 9, 1119–1129 (2000).
Neul, J. L. et al. The array of clinical phenotypes of males with mutations in methyl-CpG binding protein 2. Am. J. Med. Genet. B Neuropsychiatr. Genet. 180, 55–67 (2019).
Banerjee, A., Miller, M. T., Li, K., Sur, M. & Kaufmann, W. E. Towards a better diagnosis and treatment of Rett syndrome: a model synaptic disorder. Brain 142, 239–248 (2019).
Neul, J. L. et al. Developmental delay in Rett syndrome: data from the natural history study. J. Neurodev. Disord. 6, 20 (2014).
Leonard, H., Cobb, S. & Downs, J. Clinical and biological progress over 50 years in Rett syndrome. Nat. Rev. Neurol. 13, 37–51 (2017).
Neul, J. L. et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol. 68, 944–950 (2010).
Peters, S. U. et al. Phenotypic features in MECP2 duplication syndrome: effects of age. Am. J. Med. Genet. A 185, 362–369 (2021).
Pardinas, A. F. et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat. Genet. 50, 381–389 (2018).
Palmer, D. S. et al. Exome sequencing in bipolar disorder identifies AKAP11 as a risk gene shared with schizophrenia. Nat. Genet. 54, 541–547 (2022).
Singh, T. et al. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nat. Neurosci. 19, 571–577 (2016).
Katrancha, S. M. et al. Neurodevelopmental disease-associated de novo mutations and rare sequence variants affect TRIO GDP/GTP exchange factor activity. Hum. Mol. Genet. 26, 4728–4740 (2017).
Bachmann, S., Degen, C., Geider, F. J. & Schroder, J. Neurological soft signs in the clinical course of schizophrenia: results of a meta-analysis. Front. Psychiatry 5, 185 (2014).
Schroder, J. et al. Neurological soft signs in schizophrenia. Schizophr. Res. 6, 25–30 (1991).
Bachmann, S. & Schroder, J. Neurological soft signs in schizophrenia: an update on the state- versus trait-perspective. Front. Psychiatry 8, 272 (2017).
Chan, R. C. K. et al. Neurological soft signs precede the onset of schizophrenia: a study of individuals with schizotypy, ultra-high-risk individuals, and first-onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 268, 49–56 (2018).
Takata, A. et al. Loss-of-function variants in schizophrenia risk and SETD1A as a candidate susceptibility gene. Neuron 82, 773–780 (2014).
Kummeling, J. et al. Characterization of SETD1A haploinsufficiency in humans and Drosophila defines a novel neurodevelopmental syndrome. Mol. Psychiatry 26, 2013–2024 (2021).
Owen, M. J., Sawa, A. & Mortensen, P. B. Schizophrenia. Lancet 388, 86–97 (2016).
Gecz, J. et al. Characterization of the human glutamate receptor subunit 3 gene (GRIA3), a candidate for bipolar disorder and nonspecific X-linked mental retardation. Genomics 62, 356–368 (1999).
Guilmatre, A. et al. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Arch. Gen. Psychiatry 66, 947–956 (2009).
Wu, Y. et al. Mutations in ionotropic AMPA receptor 3 alter channel properties and are associated with moderate cognitive impairment in humans. Proc. Natl Acad. Sci. USA 104, 18163–18168 (2007).
Davies, B. et al. A point mutation in the ion conduction pore of AMPA receptor GRIA3 causes dramatically perturbed sleep patterns as well as intellectual disability. Hum. Mol. Genet. 26, 3869–3882 (2017).
Trivisano, M. et al. GRIA3 missense mutation is cause of an x-linked developmental and epileptic encephalopathy. Seizure 82, 1–6 (2020).
Piard, J. et al. The GRIA3 c.2477G > A variant causes an exaggerated startle reflex, chorea, and multifocal myoclonus. Mov. Disord. 35, 1224–1232 (2020).
Kosmicki, J. A. et al. Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples. Nat. Genet. 49, 504–510 (2017).
Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. Nature 542, 433–438 (2017).
Ba, W. et al. TRIO loss of function is associated with mild intellectual disability and affects dendritic branching and synapse function. Hum. Mol. Genet. 25, 892–902 (2016).
Barbosa, S. et al. Opposite modulation of RAC1 by mutations in TRIO is associated with distinct, domain-specific neurodevelopmental disorders. Am. J. Hum. Genet. 106, 338–355 (2020).
Pengelly, R. J. et al. Mutations specific to the Rac-GEF domain of TRIO cause intellectual disability and microcephaly. J. Med. Genet. 53, 735–742 (2016).
Sadybekov, A., Tian, C., Arnesano, C., Katritch, V. & Herring, B. E. An autism spectrum disorder-related de novo mutation hotspot discovered in the GEF1 domain of Trio. Nat. Commun. 8, 601 (2017).
De Rubeis, S. et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515, 209–215 (2014).
Bourgeron, T. A synaptic trek to autism. Curr. Opin. Neurobiol. 19, 231–234 (2009).
Sperandeo, A. et al. Cortical neuronal hyperexcitability and synaptic changes in SGCE mutation-positive myoclonus dystonia. Brain https://doi.org/10.1093/brain/awac365 (2022).
Patzke, C. et al. Analysis of conditional heterozygous STXBP1 mutations in human neurons. J. Clin. Invest. 125, 3560–3571 (2015).
Saifee, O., Wei, L. & Nonet, M. L. The Caenorhabditis elegans unc-64 locus encodes a syntaxin that interacts genetically with synaptobrevin. Mol. Biol. Cell 9, 1235–1252 (1998).
Vardar, G. et al. Distinct functions of syntaxin-1 in neuronal maintenance, synaptic vesicle docking, and fusion in mouse neurons. J. Neurosci. 36, 7911–7924 (2016).
Mishima, T. et al. Syntaxin 1B regulates synaptic GABA release and extracellular GABA concentration, and is associated with temperature-dependent seizures. J. Neurochem. 156, 604–613 (2021).
Zhang, C. et al. A neuroligin-4 missense mutation associated with autism impairs neuroligin-4 folding and endoplasmic reticulum export. J. Neurosci. 29, 10843–10854 (2009).
Tian, C., Paskus, J. D., Fingleton, E., Roche, K. W. & Herring, B. E. Autism spectrum disorder/intellectual disability-associated mutations in trio disrupt neuroligin 1-mediated synaptogenesis. J. Neurosci. 41, 7768–7778 (2021).
Arons, M. H. et al. Autism-associated mutations in ProSAP2/Shank3 impair synaptic transmission and neurexin–neuroligin-mediated transsynaptic signaling. J. Neurosci. 32, 14966–14978 (2012).
Lisman, J. & Raghavachari, S. A unified model of the presynaptic and postsynaptic changes during LTP at CA1 synapses. Sci. STKE 2006, re11 (2006).
Amador, A. et al. Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice. Brain 143, 2039–2057 (2020).
Mota Vieira, M. et al. An epilepsy-associated GRIN2A rare variant disrupts CaMKIIɑ phosphorylation of GluN2A and NMDA receptor trafficking. Cell Rep. 32, 108104 (2020).
Moutin, E. et al. Restoring glutamate receptosome dynamics at synapses rescues autism-like deficits in Shank3-deficient mice. Mol. Psychiatry 26, 7596–7609 (2021).
Jan, Y. N. & Jan, L. Y. Branching out: mechanisms of dendritic arborization. Nat. Rev. Neurosci. 11, 316–328 (2010).
Wong, R. O. & Ghosh, A. Activity-dependent regulation of dendritic growth and patterning. Nat. Rev. Neurosci. 3, 803–812 (2002).
Llamosas, N. et al. SYNGAP1 controls the maturation of dendrites, synaptic function, and network activity in developing human neurons. J. Neurosci. 40, 7980–7994 (2020).
Wang, S. et al. Loss-of-function variants in the schizophrenia risk gene SETD1A alter neuronal network activity in human neurons through the cAMP/PKA pathway. Cell Rep. 39, 110790 (2022).
Keil, K. P. et al. Genetic mutations in Ca2+ signaling alter dendrite morphology and social approach in juvenile mice. Genes. Brain Behav. 18, e12526 (2019).
Hodges, J. L. et al. Astrocytic contributions to synaptic and learning abnormalities in a mouse model of fragile X syndrome. Biol. Psychiatry 82, 139–149 (2017).
Yan, Q. J., Rammal, M., Tranfaglia, M. & Bauchwitz, R. P. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49, 1053–1066 (2005).
Comery, T. A. et al. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc. Natl Acad. Sci. USA 94, 5401–5404 (1997).
Irwin, S. A., Galvez, R. & Greenough, W. T. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb. Cortex 10, 1038–1044 (2000).
Li, X. et al. An autism-related, nonsense Foxp1 mutant induces autophagy and delays radial migration of the cortical neurons. Cereb. Cortex 29, 3193–3208 (2019).
Xu, Q. et al. Autism-associated CHD8 deficiency impairs axon development and migration of cortical neurons. Mol. Autism 9, 65 (2018).
Huang, G. et al. Uncovering the functional link between SHANK3 deletions and deficiency in neurodevelopment using iPSC-derived human neurons. Front. Neuroanat. 13, 23 (2019).
Durand, C. M. et al. SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol. Psychiatry 17, 71–84 (2012).
Zhang, L. et al. Altered dendritic morphology of Purkinje cells in Dyt1 ΔGAG knock-in and purkinje cell-specific Dyt1 conditional knockout mice. PLoS ONE 6, e18357 (2011).
Ophoff, R. A. et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87, 543–552 (1996).
Le Roux, M. et al. CACNA1A-associated epilepsy: electroclinical findings and treatment response on seizures in 18 patients. Eur. J. Paediatr. Neurol. 33, 75–85 (2021).
Khosravani, H. & Zamponi, G. W. Voltage-gated calcium channels and idiopathic generalized epilepsies. Physiol. Rev. 86, 941–966 (2006).
Miao, Q. L., Herlitze, S., Mark, M. D. & Noebels, J. L. Adult loss of Cacna1a in mice recapitulates childhood absence epilepsy by distinct thalamic bursting mechanisms. Brain 143, 161–174 (2020).
Ernst, W. L., Zhang, Y., Yoo, J. W., Ernst, S. J. & Noebels, J. L. Genetic enhancement of thalamocortical network activity by elevating ɑ1G-mediated low-voltage-activated calcium current induces pure absence epilepsy. J. Neurosci. 29, 1615–1625 (2009).
Bhat, S. et al. CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. Prog. Neurobiol. 99, 1–14 (2012).
Wheeler, D. G. et al. CaV1 and CaV2 channels engage distinct modes of Ca2+ signaling to control CREB-dependent gene expression. Cell 149, 1112–1124 (2012).
Freir, D. B. & Herron, C. E. Inhibition of L-type voltage dependent calcium channels causes impairment of long-term potentiation in the hippocampal CA1 region in vivo. Brain Res. 967, 27–36 (2003).
Moosmang, S. et al. Role of hippocampal CaV1.2 Ca2+ channels in NMDA receptor-independent synaptic plasticity and spatial memory. J. Neurosci. 25, 9883–9892 (2005).
Ali, F. et al. Inhibitory regulation of calcium transients in prefrontal dendritic spines is compromised by a nonsense Shank3 mutation. Mol. Psychiatry 26, 1945–1966 (2021).
Kutschenko, A. et al. Functional and molecular properties of DYT-SGCE myoclonus-dystonia patient-derived striatal medium spiny neurons. Int. J. Mol. Sci. 22, 3565 (2021).
Pederick, D. T. et al. Abnormal cell sorting underlies the unique X-linked inheritance of PCDH19 epilepsy. Neuron 97, 59–66.e5 (2018).
Borghi, R. et al. Dissecting the role of PCDH19 in clustering epilepsy by exploiting patient-specific models of neurogenesis. J Clin Med 10, 2754 (2021).
Nomura, T. et al. Interneuron dysfunction and inhibitory deficits in autism and fragile X syndrome.Cells 10, 2610 (2021).
Yang, W. P. et al. Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy. J. Biol. Chem. 273, 19419–19423 (1998).
Simkin, D. et al. Dyshomeostatic modulation of Ca2+ activated K+ channels in a human neuronal model of KCNQ2 encephalopathy. Elife 10, e64434 (2021).
Niday, Z., Hawkins, V. E., Soh, H., Mulkey, D. K. & Tzingounis, A. V. Epilepsy-associated KCNQ2 channels regulate multiple intrinsic properties of layer 2/3 pyramidal neurons. J. Neurosci. 37, 576–586 (2017).
Kramvis, I. et al. Dysregulated prefrontal cortex inhibition in prepubescent and adolescent fragile X mouse model. Front. Mol. Neurosci. 13, 88 (2020).
Maltese, M. et al. Abnormal striatal plasticity in a DYT11/SGCE myoclonus dystonia mouse model is reversed by adenosine A2A receptor inhibition. Neurobiol. Dis. 108, 128–139 (2017).
Scarduzio, M. et al. Strength of cholinergic tone dictates the polarity of dopamine D2 receptor modulation of striatal cholinergic interneuron excitability in DYT1 dystonia. Exp. Neurol. 295, 162–175 (2017).
Maltese, M. et al. Early structural and functional plasticity alterations in a susceptibility period of DYT1 dystonia mouse striatum. Elife 7, e33331 (2018).
Yu, F. H. et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat. Neurosci. 9, 1142–1149 (2006).
Ogiwara, I. et al. NaV1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J. Neurosci. 27, 5903–5914 (2007).
Hedrich, U. B. et al. Impaired action potential initiation in GABAergic interneurons causes hyperexcitable networks in an epileptic mouse model carrying a human NaV1.1 mutation. J. Neurosci. 34, 14874–14889 (2014).
Uchino, K. et al. Inhibitory synaptic transmission is impaired at higher extracellular Ca2+ concentrations in Scn1a+/− mouse model of Dravet syndrome. Sci. Rep. 11, 10634 (2021).
Han, S. et al. Autistic-like behaviour in Scn1a+/− mice and rescue by enhanced GABA-mediated neurotransmission. Nature 489, 385–390 (2012).
Catterall, W. A. Dravet syndrome: a sodium channel interneuronopathy. Curr. Opin. Physiol. 2, 42–50 (2018).
Sun, X. et al. Dysfunction of Trio GEF1 involves in excitatory/inhibitory imbalance and autism-like behaviors through regulation of interneuron migration. Mol. Psychiatry 26, 7621–7640 (2021).
Lozovaya, N. et al. Early alterations in a mouse model of Rett syndrome: the GABA developmental shift is abolished at birth. Sci. Rep. 9, 9276 (2019).
Author information
Authors and Affiliations
Contributions
K.J.P. researched data for the article. All authors contributed substantially to discussion of the content and writing of the article, and reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Neurology thanks J. Schröder, P. Striano and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Peall, K.J., Owen, M.J. & Hall, J. Rare genetic brain disorders with overlapping neurological and psychiatric phenotypes. Nat Rev Neurol 20, 7–21 (2024). https://doi.org/10.1038/s41582-023-00896-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-023-00896-x
This article is cited by
-
CHD8-related disorders redefined: an expanding spectrum of dystonic phenotypes
Journal of Neurology (2024)
